ALKS

Alkermes Inc. plc

29.95

USD

ALKS Earnings Reports

Positive Surprise Ratio

ALKS beat 32 of 41 last estimates.

78%

Next Report

Date of Next Report

Apr 29, 2026

Estimate for Q1 26 (Revenue/ EPS)

$367.53M

-$0.58

Implied change from Q4 25 (Revenue/ EPS)

-4.43%

-307.14%

Implied change from Q1 25 (Revenue/ EPS)

+19.91%

-323.08%

Alkermes Inc. plc earnings per share and revenue

On Feb 25, 2026, ALKS reported earnings of 0.28 USD per share (EPS) for Q4 25, missing the estimate of 0.34 USD, resulting in a -16.95% surprise. Revenue reached 384.55 million, compared to an expected 390.62 million, with a -1.56% difference. The market reacted with a -7.04% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.58 USD, with revenue projected to reach 367.53 million USD, implying an decrease of -307.14% EPS, and decrease of -4.43% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Alkermes Inc. plc's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Alkermes Inc. plc reported EPS of $0.28, missing estimates by -16.95%, and revenue of $384.55M, -1.56% below expectations.

How did the market react to Alkermes Inc. plc's Q4 2025 earnings?

The stock price moved down -7.04%, changed from $33.39 before the earnings release to $31.04 the day after.

When is Alkermes Inc. plc expected to report next?

The next earning report is scheduled for Apr 29, 2026.

What are the forecasts for Alkermes Inc. plc's next earnings report?

Based on 9 analysts, Alkermes Inc. plc is expected to report EPS of -$0.58 and revenue of $367.53M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.